Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety

ABSTRACT Aims Despite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short‐term eff...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2024-04, Vol.26 (4), p.938-947
Main Authors: Lang, Frederick M., Teruya, Sergio, Weinsaft, Ariel, Cuomo, Margaret, Santos, Alfonsina Mirabal, Nalbandian, Ani, Bampatsias, Dimitrios, Maurer, Mathew S.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Amyloid Neuropathies, Familial - drug therapy
Cardiac amyloidosis
Cardiomyopathies - drug therapy
Female
Guideline‐directed medical therapy
Heart failure
Humans
Male
Preserved ejection fraction
Retrospective Studies
SGLT2 inhibitor
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Transthyretin amyloid
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Aims Despite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short‐term efficacy and safety of SGLT2i in ATTR‐CM. Methods and results We screened consecutive patients seen at a tertiary care centre and identified 87 ATTR‐CM patients treated with SGLT2i and 95 untreated control patients. Endpoints included changes in weight, loop diuretic dose, and cardiac/renal biomarkers. The median age of the overall population was 79 (interquartile range [IQR] 11) years. Nearly 90% of patients were male, and 93% were on a transthyretin stabilizer. Control patients demonstrated generally less severe disease at baseline compared to SGLT2i‐treated patients, with lower median Columbia risk score (p 
ISSN:1388-9842
1879-0844
1879-0844
DOI:10.1002/ejhf.3198